SCHEMBL23930592

SCHEMBL23930592

COCC(C)NC(=O)c1cc(C(=O)c2sc(Nc3ccc(F)cc3)nc2N)on1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
NPC1 O15118 4/20 0.52
MAPT P10636 3/20 0.51
POLB P06746 3/20 0.51
TP53 P04637 3/20 0.49
CCNA2 P20248 2/20 0.46
CDK2 P24941 2/20 0.46
CDK5 Q00535 5/20 0.46
CDK5R1 Q15078 5/20 0.46
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
ATM Q13315 1/20 0.45
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TUBB8B A6NNZ2 1/20 0.43
TUBB4A P04350 1/20 0.43
TUBB P07437 1/20 0.43
TUBB4B P68371 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30210865 1.00 MEN1 (0.52) MEN1KMT2ANPC1MAPTPOLB
SCHEMBL23930463 0.90 MAPT (0.57) MEN1KMT2ANPC1MAPTPOLB
SCHEMBL23930639 0.86 MAPT (0.55) MEN1KMT2ANPC1MAPTPOLB
SCHEMBL30210885 0.86 MAPT (0.55) MEN1KMT2ANPC1MAPTPOLB
SCHEMBL23930643 0.85 MAPT (0.53) MEN1KMT2ANPC1MAPTPOLB
SCHEMBL23930462 0.84 NPC1 (0.42) MEN1KMT2ANPC1MAPTPOLB
SCHEMBL23930526 0.81 MAPT (0.55) MEN1KMT2ANPC1MAPTPOLB
SCHEMBL23930511 0.81 CCNA2 (0.60) MEN1KMT2ANPC1MAPTPOLB
SCHEMBL23930542 0.81 KDM4E (0.59) MEN1KMT2ANPC1MAPTPOLB
SCHEMBL30210871 0.78 LMNA (0.55) MEN1KMT2ANPC1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4139287-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 EP disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
EP-4139287-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2023-03-01 EP disclosed
CN-115697979-A Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2023-02-03 CN disclosed
WO-2021214020-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG MEN1 4290/4885KMT2A 1166/4885NPC1 3360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.